1F4CD8D0-E2FD-45AA-8CE2-8C0488916778
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.976346911957949
- age_years
- 49
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.659
- MYC_TARGETS_V1+0.626
- G2M_CHECKPOINT+0.583
- MYC_TARGETS_V2+0.547
- DNA_REPAIR+0.483
- MTORC1_SIGNALING+0.467
- UNFOLDED_PROTEIN_RESPONSE+0.439
- HYPOXIA+0.431
- GLYCOLYSIS+0.411
- OXIDATIVE_PHOSPHORYLATION+0.396
Top 10 suppressed
- KRAS_SIGNALING_DN-0.269
- MYOGENESIS-0.266
- BILE_ACID_METABOLISM-0.230
- ESTROGEN_RESPONSE_EARLY-0.187
- INTERFERON_ALPHA_RESPONSE-0.120
- APICAL_SURFACE-0.114
- COAGULATION-0.109
- INFLAMMATORY_RESPONSE-0.107
- ALLOGRAFT_REJECTION-0.085
- INTERFERON_GAMMA_RESPONSE-0.064
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 113340B4-B092-4B8C-8A13-5932525B0C33 | — | — | 0.957 |
| 2 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.932 |
| 3 | 5E729BD1-654D-4334-A80F-3EDD472551B4 | — | — | 0.918 |
| 4 | 109ABE6B-033D-47E8-A03A-D285BE82C17B | — | — | 0.898 |
| 5 | 58A2E073-D3DE-44B2-9065-3DE14B53B3A2 | — | — | 0.896 |
| 6 | SRR1313139 | — | E | 0.879 |
| 7 | DAE9D154-5E0C-4961-9110-9E5653AAA787 | — | — | 0.878 |
| 8 | A21DDF04-BECE-498B-81EA-F6953CD30D82 | — | — | 0.875 |
| 9 | SRR934935 | — | — | 0.875 |
| 10 | SRR934967 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.659 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.626 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.583 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.547 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.483 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.467 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.439 | Idelalisib | — uncovered |
| HYPOXIA | 0.431 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.411 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.396 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.388 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.381 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.312 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.303 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.283 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.272 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.226 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.222 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.214 | Inavolisib | — uncovered |